ENTITY
SMARTSCORE: 3.6/5
WuXi XDC Cayman

WuXi XDC Cayman (2268 HK)

95
Analysis
Health CareChina
WuXi XDC Cayman Inc. operates as a leading contract testing, development and manufacturing organization focused on the global antibody drug conjugates and broader bioconjugate market. The Company provides bioconjugation discovery, analytical development, intermediate and conjugation manufacturing, and other services. WuXi XDC Cayman provides its services worldwide.
more
bearishMedtide
20 Jun 2025 07:36

Medtide (泰德医药) IPO: Aggressive Valuation

​Chinese CDMO Medtide launches IPO in Hong Kong to raise up to US$66m. We think its valuation and guidance are aggressive despite being a niche...

Logo
295 Views
Share
bullishWuxi Biologics
13 Jun 2025 10:46

Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain

Wuxi Biologics Holdings is looking to raise up to US$288m by selling about 2% of Wuxi Biologics (2269 HK). This will be the 17th placement in the...

Logo
593 Views
Share
10 Jun 2025 11:18

Keymed Bioscience Placement - Track Record Isn’t Great but Recent Performance Has Been Better

Keymed Biosciences (2162 HK), along with its controlling shareholder, is looking to raise around US$112m to fund its R&D requirements.

Logo
341 Views
Share
22 May 2025 23:07

Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey

Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing....

Logo
317 Views
Share
18 May 2025 02:05

HK Connect Flows Weekly (May 16th): Biggest Weekly Outflows in a Year

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for CCB, BOC, CMB, China Shenhua Energy, CNOOC, Tencent,...

Logo
341 Views
Share
x